Background: Because little information is available about the public's awareness of and attitudes toward clinical research, we planned a survey on a convenience sample of health consumers. Methods: A crosssectional national survey was carried out using a questionnaire with seven multiple choice questions and two scenarios. A convenience sample of 2000 individuals aged 18 years and older was interviewed in nine out of 21 Italian regions. Results: Sixty-nine per cent reported they were aware of the existence of clinical research and 45% were aware of ethics committees; 29% and 49% indicated they would agree to participate in a prevention study or therapeutic randomized clinical trial, respectively. These percentages decreased when we asked about giving permission for a younger relative. Participants' awareness, opinions and attitudes varied significantly according to socio-demographic and geographical variables. People who were aware of clinical research tended to have a more open attitude toward participation [preventive study: odds ratio (OR) 1.6, 95% confidence interval (CI) 1.3-2.0, P ¼ 0.001; therapeutic study: OR 1.3, 95% CI 1.1-1.6, P ¼ 0.003), even after adjustment for confounding factors. A comparison with an independent and random sample of Italian citizens documented a difference in relevant case-mix factors and a different profile in terms of awareness, opinion and attitudes, which held after statistical adjustment. Conclusions: Health consumers are generally not very aware of clinical research, and their attitudes towards participation seem to be related to the level of awareness. A few variables, such as age, sex, schooling and area of residence, are related to the study questions. These findings may help with the implementation of educational interventions, and underline the need to create meaningful partnerships between health professionals and consumer associations.
M
edical progress is largely based on clinical research, and with the emergence of evidence-based medicine great emphasis is placed on findings from clinical trials, as a basis for health-care decisions at either individual or policy level. 1, 2 The emphasis on the use of randomization to achieve unbiased evidence makes a vital distinction between clinical practice and clinical research, calling for a correct perception of the rationale underlying any experiments involving human subjects, and emphasizes the role and participation of patients in, and their attitude towards, clinical trials. 3, 4 With the emphasis laid on preventive medicine, large groups from the general population may will be enrolled in clinical trials, and general practitioners (GPs) will play an important role in pharmacological and nonpharmacological prevention studies. The doctor-patient interaction and communication will become more complex and the potential conflict between medical ethics and human rights more acute.
Notwithstanding, there is very little systematic evidence about the public's awareness of these issues. 5, 6 Most studies have looked at patients with specific conditions, and misconceptions about clinical trials are frequent; the involvement of health consumers in trials is viewed as favourable by researchers but is rarely actually implemented; the level of participation in clinical trials is low, and is often further reduced by factors not related to patients' awareness or willingness. [7] [8] [9] [10] Given the lack of information from citizens and health consumers, who are presumably healthier and more risk-adverse than patients, the Mario Negri Institute for Pharmacological Research (www.marionegri.it) and a voluntary association for the defence of consumer rights, 'Movimento dei Cittadini' (http://space.tin. it/salute/giorighe), started working together in 1999 to stimulate a debate about participation in clinical research. Two surveys were carried out on two samples of Italian health consumers and citizens between 2000 and 2001. Here we report the results of the analysis carried out on the sample of health consumers and discuss the implications of these results by comparing the present findings with those obtained from a sample of citizens that were published elsewhere. 11 
Methods
The data presented are part of a wider project that has been implemented over a 2-year period in three steps. First, a questionnaire was developed and empirically tested; then a random sample of Italian citizens was identified and interviewed at home; and finally, a convenience sample of health consumers, namely people seeking care at GPs' offices or in outpatient clinics, was interviewed.
Overall, more than 3000 individuals were involved and interviewed throughout Italy. Elsewhere we have reported results from the random sample of Italian citizens. 11 
Questionnaire
A preliminary version of the questionnaire was assembled using information from the literature. It was then reviewed by experts not directly involved in the study design, tested in a small independent sample of health consumers, then administered twice to a small group of students. Debriefing interviews to test face validity and formally evaluate reliability showed which were the most valid and reliable questions. The final version was divided into two sections, the first regarding awareness and opinions about general issues pertaining to clinical research and the second regarding the attitude towards participation in clinical trials. Briefly, the first section asked two questions about the awareness of clinical trials and ethics committees ('Have you ever heard about clinical research?', 'Have you ever heard about ethics committees?'), two about the basic guarantees required to enter a clinical trial ('Who should be responsible for the quality of a clinical study?', 'What information is essential for participating in a clinical trial?'), two about the proponent ('Who should be the proposing physician?', 'Would you participate in a clinical trial led by your general practitioner?') and one about why such studies are carried out ('Why should a physician propose a clinical trial?'). The second section included two scenarios, one describing a prevention study that involves giving a new influenza vaccine to healthy people, and the other a randomized clinical trial testing the efficacy of a new drug for early acute myocardial infarction (see table 4 for details). People were asked to indicate whether they would agree to enter such trials, then were asked to make a choice on behalf of relatives younger than 18 years old. A cover letter was included explaining the aim of the survey and introducing the standard methods used to develop and test new drugs, together with a section asking for standard socio-demographic data such as age, sex, education, area of residence and self-reported health conditions.
Sample and interview
A non-probabilistic convenience sample of people seeking care at a GPs' offices or outpatient clinics was interviewed by trained interviewers. On the basis of official figures from the last census of the Italian population, a total sample of at least 2000 individuals was designed to reproduce the expected proportions of individuals aged 18 years and older according with area of residence (North, Centre or South of the country), sex and age.
In nine (out of 21) Italian regions (four in the North, two in the Centre and three in the South), interviewers were instructed to identify and recruit a fixed quota of eligible cases. They first identified eligible cases in GPs' offices or outpatient clinics, then introduced the survey and asked for participation; people who accepted were asked to complete the questionnaire. Self-administration was recommended, but interviewers were allowed to read or explain questions if necessary. No information was collected about the number of eligible people actually contacted but not included in the survey.
Statistical analysis
All questionnaires collected were checked and validated by the Movimento dei Cittadini coordinating centre in Verona, then analysed at the IRFMN at Milan.
Associations between potential determinants and individuals' answers were estimated using odds ratios (OR) and the corresponding 95% confidence intervals (95% CI). Stratified analysis was used to control for the effect of each of the potential confounders and, when appropriate, Mantel-Haenszel overall and linear x 2 -tests for associations were used. 12 The frequency of the responses varied because of some missing or non-valid answers, and because in some cases more than one answer was possible.
Results

Sample characteristics
A total of 2000 people were interviewed between May and June 2000 and included in the analysis. When compared with the random sample of Italian citizens, health consumers appeared to be somewhat older, more educated, more frequently located in Northern Italy and with more self-reported health conditions (table 1) . These differences are explained by the intrinsic characteristics of the samples (people seeking care versus healthy citizens) and by the methods of recruitment adopted (convenience versus random sampling), as reported fully in Methods, and in a previously published paper. 11 The implications of these differences are fully discussed in the Discussion. Most cases (69%) required no help to fill in the questionnaire, and questions were read in 19% and explained in 12% of cases.
Awareness and opinions about issues related to clinical trials
Two-thirds of the participants reported they were aware of the existence of clinical research, and 45% of ethics committees. As to which institutions should be in charge of clinical research, most indicated research institutes or university hospital, while only a few indicated pharmaceutical companies or private hospitals.
As to the type of information they would consider essential before entering a clinical study, most indicated the availability of information on the risk-benefit ratio and the presence of a physician as reference during the study; a few considered it essential to know the composition of the ethics committees and required full disclosure about the study sponsor. When asked to indicate the motivations driving physicians to propose a clinical research, most indicated the progress of science and medicine and the patient's recovery or the promotion of citizens' health. Very few named academic or economic reasons. As the proposing physician, most indicated the hospital physician, but when explicitly asked whether they would enter a clinical study led by a GP, 40% said they would (table 2) .
Participants' awareness and opinions varied according to socio-demographic and geographical variables. Table 3 shows the relation between selected respondents' answers and the main variables: the probability of being aware of clinical research and ethics committees appeared to be related to age, schooling and area of residence: elderly, less educated people and those living in Southern Italy were somewhat less aware of these issues. On the question about the role of GPs, young, more educated people, those living in Southern Italy and those reporting no major health problems were less likely to indicate GPs as potential leaders of clinical studies.
Attitude towards participation in clinical trials
The attitude toward participation in clinical trials was not favourable for the prevention trial (table 4): 49% indicated they would agree to participate in the therapeutic randomized clinical trial, but only 29% agreed to the vaccination trial. When asked to state whether they would permit the participation of a younger relative in the same studies, the proportion of people Schooling: for this analysis education was classified in three levels: <5 years, 5-8 years and >8 years * P-value from Mantel-Haenszel x willing was lower, particularly for the vaccination study, with only 5% saying they would agree. A few variables were associated with the likehood of a positive attitude towards participation (table 5) : female, less educated people and those living in Southern Italy took a less positive view of the prevention trial. A different pattern was observed in the therapeutic scenario. People living in Southern Italy were more likely to participate personally and were also more likely to allow the participation of a younger relative.
Subgroup analysis and comparison with Italian citizens
Sex, age and schooling were related to participants' answers and to their area of residence. Thus, to control for the imbalance due to socio-demographic factors, we carried out a stratified analysis to evaluate the strength and statistical significance of the associations between area of residence and individuals' answers, controlling for other confounders. As the North and Centre gave similar estimates, for the purpose of the present analysis we classified this variable as follows: North and Centre versus Southern Italy. Even after adjustment for sex, age and schooling (variables describing the comorbidity status did not change the results), people living in Southern Italy were significantly less likely to be aware of clinical research-related issues (OR 0.63, 95% CI 0.52-0.78), and were less favourable towards participating in clinical studies where a GP was the proponent or principal investigator (OR 0.61, 95% CI 0.49-0.75). They were also less likely to enter a vaccination trial (OR 0.72, 95% CI 0.58-0.89), but more willing to take personally part in a therapeutic trial (OR 1.53, 95% CI 1.27-1.85 ) and to give consent for a minor to participate (OR 1.75, 95% CI 1.41-2.17).
When we compared this sample of health consumers with the citizens, 11 significant differences emerged both in terms of potential determinants (table 1) and for all but one of the seven questions considered (table 6). In order to control for the unbalance due to some confounders (education, age, comorbidities and geographical location) we performed a stratified analysis: health consumers from the convenience sample appeared to be more willing to participate in a clinical research lead by GP and to personally participate in a clinical research as a healthy volunteer, whereas citizens from the random sample were more likely to participate in, or to give consent for a minor to participate in, clinic research for a new drug.
Table 4 Respondents' attitudes toward participation in clinical trials
The first scenario was phrased as follows: Outbreaks of influenza occur every winter and have a huge impacts on society and the individual. One way to reduce the impact of the illness is to consider vaccination. Some researchers are studying a new vaccine which must now be tested on a group of healthy voluntaries. The results of this phase allow will help show whether this intervention is a safe and effective method meriting further investigation.
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Discussion
Community awareness about the need for clinical research and the manner in which it is conducted is important, as there appears to be a relation between knowledge/awareness and willingness to participate. 3 Most research on the nature of this association has been conducted in English-speaking countries, on samples of specific diseases 8, 9, 13, 14 or in samples of people from individual metropolitan areas. 15, 16 Empirical data from national surveys are very rare indeed, the only example we found in the recent literature being focused on cancer-related issues. 10 Healthy individuals and patients do not have the same perception and attitudes, healthy people being more risk-adverse than patients, and thus have a less favourable attitude towards research. 17 In addition, awareness and attitude tend to differ across a country. 6 We therefore carried out two surveys using the same questionnaire to establish the Italian public's awareness about clinical research and to identify any points that might help the implementation of specific interventions. The previous study on a random sample of 1000 Italian citizens suggested that society at large does not have a favourable attitude towards clinical research (slightly more than half said that they would participate in a therapeutic clinical trial and only about 20% indicated they would participate in a vaccination trial); a few socio-demographic and geographical variables were associated with both the awareness and the attitude toward participation, with people living in Southern Italy having a different view of clinical research. 6, 11 The present survey on a convenience sample of people seeking health care at GP or outclinic levels shows that, in general, this non-random sample of Italian health consumers is quite different from the sample of citizens in terms of case-mix, but has Schooling: for this analysis education was classified in three levels: <5 years, 5-8 years and >8 years * P-value from Mantel-Haenszel x limited awareness of issues pertaining to clinical research. It also had scant enthusiasm about participation in clinical trials, particularly for the prevention trial that required the participation of healthy minors. Some important determinants appeared to influence people's awareness, opinions and attitude, such as age, education and area of residence. Differences according to area of residence remained after adjustment for socio-demographic factors and must be kept in mind when planning interventions to change awareness or nationwide clinical studies. In addition, people who were more aware of the existence of clinical research were somewhat more likely to indicate they would enter the clinical trials outlined in the two scenarios, even after taking into account the confounding effect of the main variables. Finally, after adjusting for age, education, self-reported health conditions and geographical location, health consumers showed significative differences in all but one the seven questions considered. This survey has some limitations. First, the study design and the sampling strategy gave rise to oversampling of health consumers with a higher than expected level of schooling. This was probably due to a selection bias introduced by the recruitment strategy: interviewers in GPs' offices or outpatient clinics contacted all the consecutive people who matched the characteristics required (i.e. age, sex and area of residence) until they reached the number needed, and self-selection presumably meant that more educated people were more willing to participate. This might have introduced a distortion, with an overestimate of the level of awareness reported by the sample present findings that might not be generalized to health consumers as a whole. Secondly, in 12% of cases interviewers helped complete the questionnaire, and might just have influenced the answers, particularly since elderly or less educated people were those actually requiring more assistance. Finally, the specific scenarios we used to assess peoples' attitudes could have influenced the results, which therefore cannot be considered general indicators of people's attitudes. In other words, the use of other examples could have produced different results.
Despite these limitations, we believe that these factors did not seriously impair the results, for the following reasons. First, if a selection bias did distort the results it probably did not change the direction of the associations found, as results in the companion survey in a random sample of Italian citizens results were very similar. 11 Secondly, we carried out further analyses to test whether people receiving help answered in systematically different ways: we checked the distribution of the help across the main categories, and then introduced this variable into the model. The findings did not change at all.
Finally, although we were not able to find other studies against which to compare the validity and generalizability of our results, as those available were published several years ago or were carried out in groups with specific diseases, a few more recent papers support our findings or give additional and complementary evidence about the need to involve public representatives or health consumers in main aspect of clinical research. Ellis, 18 in a review of the literature, evaluated the issues pertinent to physician and patient participation and identified strategies to inform patients better about clinical trials. The author reported several patients' and physicians' characteristics that influence participation in randomized clinical trials, such as doctors' attitudes to randomization, logistic difficulties, ethical concerns, etc., and suggested that patients' understanding about clinical trials may play an important role. They identified at least three randomized clinical trials testing this hypothesis in cancer patients, and all confirmed that providing patients with of more information patients preserved their independence, improved recall and understanding of information, but had little or no impact on participation. 17, 19, 20 Ellis et al. 9 also carried out a cross-sectional survey on a small sample of outpatients attending a medical oncology clinic, to assess the understanding of and attitudes towards randomized clinical trials. Knowledge was not good: only one-third would consider participating in a randomized study and patients were more likely to participate if a study was endorsed by an independent cancer information service. They concluded that new strategies are needed to educate the public and patients about randomized clinical trials, and that consumers should be involved in the design and conduct of these trials.
Hanley et al. 7 administered a structured questionnaire to a sample of 103 coordinating centre involved in clinical trials in the UK to assess the extent to which consumers were involved. Of the 62 eligible responders, 23 reported that consumers had already been involved in their work and 17 said they had planned 
